TRVI Stock Price, Trevi Therapeutics Inc Quote, Chart

Market Summary

USD2.76+0.22

Market Closed

8.66%

TRVI Stock Price

View Fullscreen

TRVI RSI Chart

TRVI Valuation

Market Cap

190.3M

Price/Earnings (Trailing)

-6.55

EV/EBITDA

-5.53

Price/Free Cashflow

-5.98

MarketCap/EBT

-6.54

TRVI Price/Sales (Trailing)

TRVI Profitability

Return on Equity

-35.21%

Return on Assets

-32.51%

Free Cashflow Yield

-16.73%

TRVI Fundamentals

TRVI Earnings

Earnings (TTM)

-29.1M

Earnings Growth (Yr)

-42.07%

Earnings Growth (Qtr)

-1.6%

Breaking Down TRVI Revenue

Last 7 days

-2.8%

Last 30 days

-20.5%

Last 90 days

76.9%

Trailing 12 Months

-19.3%

How does TRVI drawdown profile look like?

TRVI Financial Health

Current Ratio

15.03

TRVI Investor Care

Shares Dilution (1Y)

14.81%

Diluted EPS (TTM)

-0.29

Tracking the Latest Insider Buys and Sells of Trevi Therapeutics Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Oct 11, 2023	delfini lisa	sold	-1,585	2.02	-785	chief financial officer
Oct 11, 2023	delfini lisa	acquired	1,171	0.511	2,292	chief financial officer
Sep 11, 2023	delfini lisa	sold	-1,564	2.2	-711	chief financial officer
Sep 11, 2023	delfini lisa	acquired	1,170	0.511	2,291	chief financial officer
Aug 11, 2023	delfini lisa	sold	-1,609	2.36	-682	chief financial officer
Aug 11, 2023	delfini lisa	acquired	1,171	0.511	2,292	chief financial officer
Jul 11, 2023	delfini lisa	acquired	1,171	0.511	2,292	chief financial officer
Jul 11, 2023	delfini lisa	sold	-1,607	2.34	-687	chief financial officer
Jun 20, 2023	simon farrell	acquired	3,193	0.511	6,250	chief commercial officer
Jun 12, 2023	delfini lisa	sold	-1,610	2.64	-610	chief financial officer

Which funds bought or sold TRVI recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 25, 2024	Bank of New York Mellon Corp	reduced	-3.56	265,032	443,763	-%
Apr 25, 2024	Rosalind Advisors, Inc.	reduced	-50.28	699,105	3,194,760	2.98%
Apr 23, 2024	AMALGAMATED BANK	reduced	-61.36	-	5,000	-%
Apr 22, 2024	RAYMOND JAMES & ASSOCIATES	new	-	34,500	34,500	-%
Apr 15, 2024	PFS Partners, LLC	unchanged	-	208,890	341,550	0.23%
Apr 05, 2024	NBC SECURITIES, INC.	unchanged	-	4,000	6,000	-%
Apr 05, 2024	CWM, LLC	new	-	-	-	-%
Apr 04, 2024	TRUST CO OF TOLEDO NA /OH/	unchanged	-	77,019	125,932	0.02%
Mar 11, 2024	VANGUARD GROUP INC	added	14.58	-1,262,010	3,006,150	-%
Mar 01, 2024	GOLDMAN SACHS GROUP INC	added	82.91	7,085	64,092	-%

Are Funds Buying or Selling TRVI?

Are funds buying TRVI calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own TRVI

No. of Funds

Unveiling Trevi Therapeutics Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Apr 25, 2024	rosalind advisors, inc.	1.34%	926,016	SC 13G/A
Feb 14, 2024	venrock healthcare capital partners ii, l.p.	9.99%	6,707,564	SC 13G/A
Feb 14, 2024	fairmount funds management llc	0.0%	0	SC 13G/A
Feb 14, 2024	viking global investors lp	9.99%	6,599,062	SC 13G/A
Feb 12, 2024	rubric capital management lp	8.90%	5,684,420	SC 13G/A
Feb 15, 2023	rosalind advisors, inc.	4.2%	2,499,993	SC 13G
Feb 14, 2023	armistice capital, llc	4.99%	3,147,200	SC 13G/A
Feb 14, 2023	venrock healthcare capital partners ii, l.p.	9.99%	6,312,192	SC 13G/A
Feb 14, 2023	fairmount funds management llc	9.9%	6,018,465	SC 13G/A
Feb 14, 2023	viking global investors lp	9.99%	6,162,362	SC 13G/A

Recent SEC filings of Trevi Therapeutics Inc

View All Filings

Date Filed	Form Type	Document
Apr 26, 2024	DEFA14A	DEFA14A
Apr 26, 2024	DEF 14A	DEF 14A
Apr 25, 2024	SC 13G/A	Major Ownership Report
Mar 20, 2024	S-8	Employee Benefits Plan
Mar 20, 2024	8-K	Current Report
Mar 20, 2024	10-K	Annual Report
Feb 16, 2024	4	Insider Trading
Feb 16, 2024	4	Insider Trading
Feb 16, 2024	4	Insider Trading
Feb 16, 2024	4	Insider Trading

Peers (Alternatives to Trevi Therapeutics Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	41.2B	6.8B	-2.42%	-17.04%	-8.75	6.02	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.0B	1.8B	-7.18%	-26.90%	-41	9.87	76.23%	61.08%
BMRN	15.4B	2.5B	-8.70%	-12.49%	74.73	6.21	13.74%	186.89%
INCY	11.6B	3.7B	-9.54%	-29.84%	19.41	3.14	8.87%	75.42%
MID-CAP
APLS	6.0B	396.6M	-14.77%	-39.78%	-11.37	15.16	425.83%	18.94%
BBIO	4.4B	-	-19.35%	75.41%	-6.7	60.35	54.84%	-34.79%
AXSM	3.4B	270.6M	-9.32%	0.89%	-14.22	12.57	440.80%	-27.84%
ACAD	2.8B	726.4M	-8.24%	-18.54%	-44.9	3.79	40.45%	71.62%
ARWR	2.7B	240.7M	-22.93%	-36.73%	-9.23	12.18	-1.03%	-92.09%
SMALL-CAP
CPRX	1.8B	398.2M	-8.48%	-5.52%	24.58	4.41	85.90%	-14.05%
NVAX	569.6M	983.7M	-16.08%	-46.16%	-1.05	0.58	-50.36%	17.16%
CRBP	361.2M	881.7K	-3.23%	346.43%	-8.1	466.16	-77.61%	-5.33%
INO	247.0M	4.9M	-18.88%	12.93%	-1.83	50.76	-54.97%	51.71%
IBIO	6.1M	2.1M	-47.62%	62.96%	-0.22	2.14	-13.45%	66.37%

Trevi Therapeutics Inc News

Latest updates

Trevi Therapeutics Inc Earnings Report: Key Takeaways & Analysis

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	-6.8%	89.00	96.00	101	116	123	128	81.00	30.00	38.00	32.00	39.00	43.00	47.00	56.00	47.00	54.00	60.00	66.00	75.00	17.00	11.00
Current Assets	-6.8%	88.00	94.00	99.00	114	123	127	80.00	30.00	38.00	31.00	38.00	42.00	46.00	55.00	46.00	54.00	60.00	66.00	75.00	15.00	9.00
Cash Equivalents	24.8%	32.00	26.00	14.00	12.00	13.00	67.00	25.00	29.00	37.00	29.00	36.00	42.00	45.00	53.00	44.00	53.00	57.00	64.00	71.00	13.00	7.00
Net PPE	-9.2%	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Liabilities	9.1%	7.00	6.00	6.00	14.00	16.00	18.00	21.00	20.00	21.00	20.00	21.00	19.00	20.00	-	-	-	-	-	-	-	-
Current Liabilities	12.6%	6.00	5.00	5.00	13.00	13.00	15.00	15.00	13.00	13.00	10.00	9.00	5.00	6.00	6.00	7.00	7.00	5.00	5.00	7.00	4.00	3.00
Shareholder's Equity	-7.9%	83.00	90.00	95.00	102	107	110	61.00	10.00	17.00	11.00	18.00	24.00	27.00	36.00	40.00	47.00	55.00	61.00	68.00	-	-
Retained Earnings	-3.4%	-239	-231	-223	-216	-210	-204	-196	-188	-180	-172	-165	-155	-146	-137	-130	-122	-114	-107	-100	-115	-109
Additional Paid-In Capital	0.2%	322	321	319	318	318	315	257	199	198	184	183	179	174	173	170	169	169	168	168	-	-
Shares Outstanding	6.9%	68.00	64.00	63.00	60.00	60.00	53.00	60.00	31.00	29.00	22.00	20.00	19.00	19.00	-	-	-	-	-	-	-	-
Float	-	-	-	106	-	-	-	65.00	-	-	-	22.00	-	-	-	42.00	-	-	-	29.00	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	12.6%	-6,359	-7,279	-9,875	-8,197	-6,331	-8,576	-6,176	-7,092	-6,229	-7,241	-7,898	-7,578	-8,924	-6,967	-8,436	-4,673	-6,202	-7,734	-5,061	-4,096	-4,732
Share Based Compensation	0.7%	534	530	606	578	501	569	520	737	540	540	745	718	510	588	589	730	373	371	237	146	185
Cashflow From Investing	-28.6%	12,845	17,982	19,639	8,962	-48,306	-4,850	-	-	-	-	-	-	-5.00	-15.00	-	-	-	-	-	-9.00	-92.00
Cashflow From Financing	-103.6%	-54.00	1,510	-7,663	-1,703	652	55,302	55,978	-625	13,741	134	2,753	4,147	637	16,095	-	-	-	-138	63,502	9,849	-1,508

TRVI Income Statement

2023-12-31

Consolidated Statements of Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Operating expenses:
Research and development	$ 23,683	$ 19,834
General and administrative	10,240	10,073
Total operating expenses	33,923	29,907
Loss from operations	(33,923)	(29,907)
Other income (expense):
Interest income, net	4,748	1,740
Other income, net	469	289
Interest expense	(391)	(1,163)
Change in fair value of term loan derivative liability		(147)
Total other income, net	4,826	719
Loss before income taxes	(29,097)	(29,188)
Income tax benefit	32	36
Net loss	$ (29,065)	$ (29,152)
Basic net loss per common share outstanding	$ (0.29)	$ (0.45)
Diluted net loss per common share outstanding	$ (0.29)	$ (0.45)
Weighted average common shares used in net loss per share attributable to common stockholders, basic	99,033,373	64,541,911
Weighted average common shares used in net loss per share attributable to common stockholders, diluted	99,033,373	64,541,911
Net loss	$ (29,065)	$ (29,152)
Other comprehensive loss:
Net unrealized gains (losses) on available-for-sale marketable securities	93	(122)
Comprehensive loss	$ (28,972)	$ (29,274)

TRVI Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 32,397	$ 12,589
Marketable securities	50,574	107,921
Prepaid expenses	3,621	795
Other current assets	955	1,311
Total current assets	87,547	122,616
Operating lease right-of-use assets	1,137	24
Other non-current assets	297	205
Property, equipment and leasehold improvements, net	216	170
Finance lease right-of-use assets	206
Total assets	89,403	123,015
Current liabilities:
Accounts payable	1,809	2,857
Accrued expenses	3,709	3,518
Operating lease liabilities	184	25
Finance lease liabilities	122
Term loan		7,000
Total current liabilities	5,824	13,400
Operating lease liabilities	1,001	2
Finance lease liabilities	31
Term loan		2,151
Other non-current liabilities		3
Total liabilities	6,856	15,556
Commitments and contingencies (Note 13)
Stockholders’ equity:
Preferred stock: $0.001 par value; 5,000,000 shares authorized at December 31, 2023 and December 31, 2022; no shares issued or outstanding at December 31, 2023 and December 31, 2022.
Common stock: $0.001 par value; 200,000,000 shares authorized at December 31, 2023 and December 31, 2022; and 68,283,699 and 59,943,430 shares issued and outstanding at December 31, 2023 and December 31, 2022, respectively.	68	60
Additional paid-in capital	321,642	317,590
Accumulated other comprehensive loss	(29)	(122)
Accumulated deficit	(239,134)	(210,069)
Total stockholders’ equity	82,547	107,459
Total liabilities and stockholders’ equity	$ 89,403	$ 123,015

About Trevi Therapeutics Inc

Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio for the treatment of serious cough conditions targeting the central and peripheral nervous systems. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b/3 clinical trial for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.

CEO	Ms. Jennifer L. Good
WEBSITE	trevitherapeutics.com
INDUSTRY	Biotechnology
EMPLOYEES	30

Trevi Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for Trevi Therapeutics Inc? What does TRVI stand for in stocks?

TRVI is the stock ticker symbol of Trevi Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Trevi Therapeutics Inc (TRVI)?

As of Fri Apr 26 2024, market cap of Trevi Therapeutics Inc is 190.33 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of TRVI stock?

You can check TRVI's fair value in chart for subscribers.

What is the fair value of TRVI stock?

You can check TRVI's fair value in chart for subscribers. The fair value of Trevi Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Trevi Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for TRVI so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Trevi Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether TRVI is over valued or under valued. Whether Trevi Therapeutics Inc is cheap or expensive depends on the assumptions which impact Trevi Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for TRVI.